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ABSTRACT
RAD51, a key protein in the homologous
recombinational DNA repair (HRR) pathway, is the
major strand-transferase required for mitotic
recombination. An important early step in HRR is
the formation of single-stranded DNA (ss-DNA)
coated by RPA (a ss-DNA-binding protein).
Displacement of RPA by RAD51 is highly regulated
and facilitated by a number of different pro-
teins known as the ‘recombination mediators’. To
assist these recombination mediators, a second
group of proteins also is required and we are
defining these proteins here as ‘recombination
co-mediators’. Defects in either recombination
mediators or co-mediators, including BRCA1 and
BRCA2, lead to impaired HRR that can geneti-
cally be complemented for (i.e. suppressed) by
overexpression of RAD51. Defects in HRR have
long been known to contribute to genomic insta-
bility leading to tumor development. Since
genomic instability also slows cell growth,
precancerous cells presumably require genomic
re-stabilization to gain a growth advantage.
RAD51 is overexpressed in many tumors, and
therefore, we hypothesize that the complement-
ing ability of elevated levels of RAD51 in
tumors with initial HRR defects limits genomic
instability during carcinogenic progression. Of
particular interest, this model may also help
explain the high frequency of TP53 mutations in
human cancers, since wild-type p53 represses
RAD51 expression.
INTRODUCTION
Homologous recombinational DNA repair plays
an important role in cancer
The central protein involved in the homologous
recombinational DNA repair (HRR) pathway is
RAD51, a strand transfer protein. Although no mutations
in the RAD51 open reading frame have been found in
cancers, defects in other HRR genes have been shown to
play an important role in carcinogenesis, and particularly
in breast cancer. Inherited heteroallelic mutations in
BRCA1 and BRCA2 each result in a breast cancer predis-
position syndrome, and both of these genes are involved in
HRR (1). In addition, eight more breast cancer predispo-
sition syndromes have been identiﬁed, and all of these also
involve defects in HRR-related genes (2). There have been
several excellent and comprehensive reviews in recent
years that describe the connections between HRR and
cancer (particularly breast cancer) (1,3), the role of TP53
mutations in recombination (4,5) and the observation that
RAD51 is overexpressed in many tumors (6). What seems
to be missing from these and other reviews is an overall
hypothesis explaining the relationship between these three
diﬀerent components of carcinogenesis. Here, we review
what we feel is the missing link that helps tie these com-
ponents together. This missing link is the observation that
overexpression of RAD51 partially complements (i.e.
suppresses) defects in a number of diﬀerent HRR genes
that encode recombination mediator and co-mediator
proteins, including BRCA1 and BRCA2. Recombination
mediators and co-mediators are proteins that assist
RAD51 in displacing the single-strand DNA (ss-DNA)-
binding protein RPA from ss-DNA, thus initiating the
formation of the RAD51 ﬁlament. Complementation by
RAD51 overexpression, which has not been reviewed
before, is the central focus of this article.
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For many years it has been observed that the levels of the
RAD51 protein are greatly elevated ( 2–7-fold) in many
cancer cell lines and in primary tumors [reviewed by (6)].
The wild-type p53 protein plays an important role both in
suppressing the transcriptional expression of RAD51 and
in down-regulating RAD51 protein activity (4,5,7,8). The
advantage for cancer cells of overexpressing RAD51 has
yet to be adequately explained, but it has been suggested
that the high levels of RAD51 are involved in tumor pro-
gression by destabilizing the genome (9). Another possible
explanation is that elevated RAD51 confers a DNA rep-
lication advantage during the more rapid cell divisions
that follow the activation of oncogenes and inactivation
of tumor suppressors. Each of these explanations, at least
in their basic form, suﬀers from the fact that, in general,
overexpression of RAD51 is deleterious and slows cell
growth in vitro, and therefore would also be likely to
hinder the growth of cancer cells in vivo. Based on pub-
lished reports about the ability of overexpressed RAD51
to suppress defects in HRR genes, two new alternative
hypotheses are presented at the end of this article that
may explain why RAD51 is up-regulated in many human
cancers.
RECOMBINATION MEDIATORS AND
CO-MEDIATORS
The HRR pathway is composed of a highly orchestrated
network of proteins, many of which presumably still
remain to be discovered. HRR frequently is initiated by
a double-strand break, either due to endogenous
lesions at the replication fork, or induced by diﬀerent
DNA damaging agents, including cisplatin, mitomycin
C (MMC), camptothecin (CPT) and ionizing radiation.
First, endonucleolytic activity produces a long
30 ss-DNA overhang that is rapidly coated with RPA, the
heterotrimeric ss-DNA-binding protein. Displacement of
RPA by RAD51 is critical and highly regulated, and initi-
ates the strand transfer process (Figure 1). The proteins
directly involved in the displacement of RPA are named
‘recombination mediators’ (Table 1) (10,11) (here some-
times referred to as just ‘mediators’). Recombination
mediator activity is ideally assayed by biochemical
methods (10,12–15). In place of biochemical evidence,
reductions in RAD51 foci formation are frequently
utilized as an indirect indicator of a mediator defect
(16–18), if the defective/missing protein is not required for
the formation of RPA-coated ss-DNA. It is signiﬁcant that
mutations in most of these mediators in mammalian cells
result in high levels of genomic instability, as has been
demonstrated for cells with deletions of RAD51D in both
Chinese hamster ovary cells (CHO) and murine embryonic
ﬁbroblast cells (MEFs) (19,20). Very high levels of
mutagenesis were observed in Rad51d deletion CHO cells
(19), and increased mutagenesis seems likely in other
mediator defective cell lines as well.
There are also a number of proteins that function to
assist these mediators or localize them to the site of the
DNA break. These proteins have not previously been
given a general name, but we propose to call them ‘recom-
bination co-mediators’. Many of the mediators and
co-mediators are known tumor suppressor proteins, and
mutant versions frequently can be suppressed by over-
expression of RAD51, as discussed below. This makes
considerable biological sense, since these proteins
function to assist RAD51, but in their absence, RAD51
overexpression can in some cases partially compensate. It
is still unknown whether defects in other HRR proteins
(i.e. non-mediators such as MRE11 and RAD54) can also
be suppressed by RAD51 overexpression. Also, only some
of the mediators/co-mediators have been tested for sup-
pression by RAD51 overexpression, and there are addi-
tional proteins that may also be mediators/co-mediators,
since they interact with BRCA1 or BRCA2 (i.e. BARD1,
BCCIPa and b, BRIP1/FANCJ/BACH1 and SHFM1/
DSS1). With the use of the RNAi technique, it should
be relatively easy to test these other potential human
mediators/co-mediators for complementation by RAD51
overexpression. Ideally these experiments should be done
in human cell lines that initially express low levels of
endogenous RAD51.
FUNCTIONAL SUPPRESSION BY RAD51
OVEREXPRESSION
Functional suppression in model organisms
Overexpression of RAD51 has been shown to partially
suppress defects in recombination mediators and
Figure 1. Simpliﬁed schematic to depict the mediator step of recombi-
nation: displacement of RPA by RAD51. A critical step in homologous
re-combinational repair is the displacement of RPA, the trimeric
ssDNA-binding protein, by the RAD51 strand transfer protein. This
step is highly regulated by cells to ensure that potentially deleterious
events are avoided. Many diﬀerent proteins are involved in assisting
RAD51 to displace RPA at this stage, and the proteins that are directly
involved are known as the ‘recombination mediators’ (Table 1). There
are also additional proteins that function to assist the mediators or
assist in their localization to DNA damage, and in this review, the
proteins assisting the mediators are deﬁned as ‘recombination
co-mediators’. Human BRCA2 is a mediator that interacts directly
with approximately eight RAD51 molecules and transports them to
the site of ss-DNA bound by RPA, while PALB2 and BRCA1 are
co-mediators that directly and indirectly, respectively, interact with
BRCA2 and assist in localizing it, with RAD51 bound, to the sites
of DNA damage (for references, see Table 1). DSB, double-strand
DNA break; M/R/N, MRE11-RAD50-NBS1 complex.
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cells, although suppression of the HRR defect by exoge-
nous RAD51 is generally not as complete as the
complementation by a wild-type copy of the HRR gene
that is mutated. In addition, in these experiments many
diﬀerent end-points were assessed. For each end-point, the
relative degree of complementation by exogenous RAD51
diﬀers, for unknown reasons.
Yeast. In Saccharomyces cerevisiae, two diﬀerent groups
observed that cells with deletion mutations in RAD55
and RAD57, the two yeast RAD51 paralogs, are partially
suppressed by overexpression of RAD51 (21,22). In
addition, overexpression of RAD52 resulted in partial
suppression of both X-ray sensitivity and gene conversion
defects, and simultaneous overexpression of both RAD51
and RAD52 gave near complete suppression for both
phenotypes (21). Furthermore, although most mutations
in RAD52 are not suppressed by RAD51 overexpression,
there is one mutation in RAD52 that is suppressed (23).
Since S. cerevisiae lacks both BRCA1 and BRCA2 genes, it
is not possible to test defects in these genes for
complementation by RAD51 overexpression.
Chicken DT40 cells. The chicken DT40 cell line (p53
deﬁcient) has been extensively used to characterize DNA
repair defects. Each of the ﬁve RAD51 paralog genes has
been separately knocked out in DT40 cells, and each
knockout is partially complemented by overexpression
of human RAD51 (16,17). The complementation of
RAD51B
 /  by hRAD51 overexpression was the most
extensively studied, and very interestingly, the authors
observed signiﬁcant complementation for MMC, cisplatin
and X-ray sensitivity and for genomic instability, but
not for homologous integration events (16). This result
argues that in DT40 cells and under conditions where a
RAD51 paralog is lost, overexpression of human RAD51
largely, but not fully, ameliorates the HRR-deﬁciency.
Interestingly, this complementation occurred in
RAD51B
 /  cells in which the level of the hRAD51 was
approximately equal to the level of the endogenous avian
RAD51, suggesting that simply doubling the level of
RAD51 was suﬃcient for such suppression in these cells.
In addition, RAD51 overexpression partially comple-
mented a BRCA1 deletion, since overexpression of
human RAD51 ( 15-fold increase relative to the
endogenous protein) in BRCA1
/ DT40 cells almost
completely rescued defects in cell proliferation (i.e. slow
growth) and in DNA damage survival (Figure 2), and also
partially rescued the defect in gene targeting frequency
(24). These investigators also showed that human tumors
with BRCA1 mutations frequently exhibit elevated
RAD51 transcripts, as well as elevated transcripts of
RAD51AP1 and RAD54, encoding two relatively late
acting HRR proteins (24). This is indirect evidence that
these BRCA1-deﬁcient tumors had undergone selection
for overexpression of RAD51, RAD51AP1 and RAD54,
and the authors suggested a somewhat similar hypothesis
to the one presented here: ‘The growth and viability
defects of BRCA1-deﬁcient cells are diﬃcult to reconcile
with the deregulated growth of BRCA1-deﬁcient tumors.
The ﬁndings we present here suggest that one mechanism
by which this apparent paradox is resolved is via genetic
suppression of BRCA1 phenotypes by up-regulation of
Table 1. Human recombination mediator and co-mediator proteins
Involved in cancer
a Suppressed by RAD51
overexpression in DT40 or
human cells
References
b
Recombination mediators
BRCA2/FANCD1 Yes Yes (13,15)
RAD51 paralogs
RAD51B/RAD51L1 No evidence yet Yes (14,18,56,57)
RAD51C No evidence yet Yes (14,18,56,57)
RAD51D/RAD51L3 No evidence yet Yes (18,56,57)
XRCC2 No evidence yet Yes (18,56,57)
XRCC3 No evidence yet Yes (18,56–58)
RAD52 No evidence yet nt
c (12,59)
Recombination co-mediators
BRCA1 Yes Yes (24,60)
CHK2 Yes nt (61)
PALB2/FANCN Yes nt (60,62,63)
SWS1 No evidence yet nt (64)
Potential mediators/co-mediators Main interacting
protein partner
References
BARD1 BRCA1 (65)
BCCIPa&b BRCA2 (66)
BRIP/FANCJ/BACH1 BRCA1 (67)
DSS1/SHFM1 BRCA2 (68)
aDirect involvement in cancer, since inherited mutations result in a pre-disposition towards increased cancer, particularly breast and ovarian (1–3),
and some mutant forms are also found in sporadic cancers (3).
bTop part: recent references to recombination mediator and co-mediator functions; for additional information/references see review articles
(1,2,11,63,69,70); bottom part: references to protein interactions with BRCA1 or BRCA2.
cnt, not tested yet.
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tumors examined exhibit signiﬁcantly up-regulated expres-
sion of HR genes suggests either that there is a selection
for such up-regulation during tumor development or that
a high level of expression is a precondition for
tumorigenesis of BRCA1-deﬁcient cells.’ (24)
Functional suppression in mammalian cells
In the ﬁrst direct studies in mammalian cells, two recent
independent publications report that BRCA2 defects are
suppressed by RAD51 overexpression. In one study, the
BRCA2 mutant Capan-1 human pancreatic carcinoma cell
line (with mutant p53) was shown to be partially comple-
mented by overexpression of RAD51, assaying for cell
survival after exposure to X-rays or cisplatin (25). In
addition, complementation was better, and nearly
complete, when a mutant form of RAD51 that is resistant
to caspase-3 cleavage was expressed. In the same study,
similar results on complementation by overexpression of
wild-type RAD51 were also observed for Brca2 mutant
MEFs. In the second study, mouse hybridoma cell lines
depleted for Brca2, using stable expression of siRNA,
were studied for the eﬀect of overexpression of the
mouse Rad51, Rad52 and Rad54 proteins (26). In
mouse hybridoma cells with low levels of Brca2, the
reduced frequency of targeted integration and DNA
damage-induced Rad51 foci was partially complemented
by overexpression of Rad51, but not by overexpression of
either Rad52 or Rad54.
We have found only one relevant report that
demonstrated a lack of complementation by human
RAD51, and these experiments were carried out in
Xrcc3-deﬁcient CHO cells (27). In this study,
complementation by RAD51 was assessed using an
integrated recombinational reporter plasmid. It is
possible that, if these Xrcc3-deﬁcient CHO cells had
been tested for the cellular sensitivity to MMC or
cisplatin, a diﬀerent result with respect to RAD51
complementation would have been observed, as discussed
earlier for the DT40 RAD51B
 /  cell line (16). It is worth
noting that RAD51 is one of the most highly con-
served proteins known. Consequently, the fact that the
heterologous human RAD51 protein was expressed in
Xrcc3-deﬁcient CHO cells is unlikely to have biased the
results reported by Pierce and collaborators (27). There is
a Brca2 mutant hamster V79 cell line (with mutant Trp53)
(28), which would provide a unique tool to study whether
or not wild-type human RAD51 can complement Brca2-
deﬁciency in a hamster background.
EFFECTS OF ECTOPIC OVEREXPRESSION
OF RAD51
Since the eﬀects of RAD51 overexpression in many diﬀer-
ent cellular systems have recently been extensively
reviewed (6), the results of only some studies will be dis-
cussed here. In chicken DT40 cells with wild-type HRR,
overexpression of human RAD51 resulted in increased
cellular sensitivity to cisplatin, and this enhanced sensitiv-
ity of wild-type DT40 cells was equal to the cellular sen-
sitivity of BRCA1
/ DT40 cells that did not express
ectopic RAD51 (24). On the other hand, when RAD51
was overexpressed in the BRCA1
/ DT40 cells, near
Figure 2. Eﬀects of RAD51 overexpression in isogenic wild-type and BRCA1-deleted DT40 cells. (A) In cells with wild-type HRR, overexpression of
RAD51 results in a reduced ability to repair cisplatin-induced DNA damage. Such increased sensitivity to a DNA cross-linking agent frequently
coincides with genomic instability in untreated HRR-defective cells, presumably due to unrepaired spontaneous damage (16,17,44). (B) Alternatively,
in cells with a BRCA1 homozygous deletion, the HRR defect is complemented by RAD51 overexpression. The complemented cells also presumably
have increased genomic stability, a concept incorporated into Model I. Importantly, comparing just the cells overexpressing RAD51 (in both panels),
the BRCA1 deletions actually result in increased resistance to cisplatin, and presumably also increased genomic stability, a concept incorporated into
Model II. This ﬁgure is adapted directly from the data in Figure 2D of (24), with permission from Douglas K. Bishop and AACR.
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after both cisplatin and X-rays. These experiments suggest
that overexpression of RAD51 in cells with normal HRR
can be deleterious, while overexpression in cells with an
HRR defect can be beneﬁcial (Figure 2). (Note that the
authors did not see X-ray sensitization of wild-type DT40
cells following RAD51 overexpression, but this test is not
very sensitive, since non-homologous end-joining is the
major repair pathway for X-ray damage.)
In wild-type (i.e. HRR-proﬁcient) mammalian cells, the
eﬀects of ectopic RAD51 overexpression are somewhat
contradictory, but this may relate to the end-points
assessed, the levels of RAD51 overexpression achieved,
the fraction of RAD51 that is cytoplasmic versus
nuclear and the p53 status of the cell lines utilized. In
CHO cells, overexpression of hamster RAD51 resulted
in increased HRR, while a second study reported that
overexpression of human RAD51 in CHO cells reduced
homologous recombination at a double-strand break
(29,30). In mouse ES cells, RAD51 overexpression led to
aneuploidy and chromosomal rearrangements (9). In the
human ﬁbrosarcoma HT1080 cell line, ectopic
overexpression of human RAD51 was very deleterious
to cells, resulting in a slow growth phenotype and
increased levels of apoptosis (31).
UP-REGULATION OF RAD51 IN TUMORS AND
CANCER-DERIVED CELL LINES
Many diﬀerent cancer-derived cell lines, as well as many
tumors have been shown to have higher than normal levels
of RAD51, as recently reviewed (6). The exact cause of
this overexpression is not known, but there are important
clues. For example, wild-type p53 has been reported to
suppress the transcriptional regulation of RAD51, and
TP53 deletions and some TP53 point mutations have
been shown to up-regulate the expression of RAD51 (7).
In addition to its role in transcriptional repression of
RAD51, the wild-type p53 protein directly interacts with
the RAD51 protein, inhibiting its activity (8).
There are also a number of additional factors that
appear to play a role in RAD51 regulation. There is
evidence that transcriptional activator protein 2 (AP2),
in combination with p53, functions to down-regulate
RAD51 transcription (32). In addition, there is evidence
that the oncogenic fusion tyrosine kinase BCR/Abl, the
result of translocations, increases RAD51 expression (33)
and indirect evidence that c-Abl is also involved in
up-regulating RAD51 transcription, since imatinib
(Gleevec), a relatively speciﬁc inhibitor of c-Abl, reduced
the elevated levels of RAD51 in some cancer cell lines
(34,35). Recently, it has also been reported that unlike
p53, wild-type p63 and p73 act as inducers of both basal
and DNA-damage-induced levels of RAD51 in MEFs
(36). Although, many cancer cell lines and primary
tumors overexpress RAD51 (6), chronic hypoxia has
been shown to decrease the level of RAD51, leading to
reduced levels of HRR in hypoxic tumors that also show
increased sensitivity to DNA cross-linking agents (37,38).
In general, a more complete understanding of how
RAD51 is regulated may lead to better treatments for
cancer patients.
TP53 MUTATIONS ARE UNDER REPRESENTED
IN MISMATCH REPAIR-INITIATED CANCERS
Approximately 50% of all cancers have mutations
in TP53. In particular, cancers initiated by general
genomic instability frequently have mutations in TP53.
Alternatively, cancers initiated by mutations in genes of
the mismatch repair (MMR) pathway, and the subsequent
microsatellite instability (MSI), are less frequently
associated with mutations in TP53 (39,40). This disparate
occurrence of TP53 mutations has never been satisfacto-
rily explained. The hypothesis presented here, that one of
the main functions of mutant p53 is to up-regulate
RAD51, takes this disparity into account and provides
an explanation for it, as discussed below. It is important
to note that TP53 mutations are very heterogeneous
(4,41), and that only a few mutant versions, other than
the TP53 homozygous deletion, have been tested for their
eﬀects on up-regulating RAD51 expression.
Model I: UP-REGULATION OF RAD51
SUPPRESSES HRR DEFECTS TO
RESTABILIZE THE GENOME
We proposed that carcinogenesis is frequently initiated by
defects in HRR genes (particularly in genes encoding
recombination mediators or co-mediators) that result in
genomic instability (Figures 3A and 4A). There are
likely to be many ways for a normal cell to develop an
HRR defect, since HRR is a complex DNA repair
pathway with many known genes involved and presum-
ably some genes yet to be discovered. In addition, there is
evidence for haploinsuﬃciency for some HRR defects,
and epigenetic silencing events also may account for
compromised HRR ability. Interestingly, there is
evidence that point mutations in known HRR genes are
not common in either breast or colorectal cancers: in a
study of these two cancers, most of the transcripts from
11 cancers of each type were sequenced and only a small
number of mutations in a few HRR-related genes were
identiﬁed in cancers of the breast (i.e. BCCIP, BRCA1,
BRCA2, MRE11, FANCA and FANCM) and of the
colon (FANCG) (42). Of these, only mutations in
BRCA1 and BRCA2 are known to be suppressible by
RAD51 overexpression.
Genomic instability presumably facilitates both the acti-
vation of oncogenes and the inactivation of tumor sup-
pressor genes (with the exception of TP53, which in the
current model occurs as a later event). However, genomic
instability initiated by defects in HRR is also deleterious
due to the inhibitory eﬀects on cell growth. Therefore,
there is pressure to suppress genomic instability initiated
by HRR deﬁciencies, and TP53 mutations and/or muta-
tions in other genes are selected for partially because they
lead to the up-regulation of RAD51, which then at least
partially suppresses the initial HRR defect. It also seems
likely that due to synergistic eﬀects, some cancers may
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proteins that function later than the recombination medi-
ators/co-mediators. [Note that there is evidence that
RAD51AP1, which is not a RAD51 paralog, functions
later in HRR than the recombination mediators
(43,44), and RAD51AP1 has been shown to be
up-regulated in a number of cancers (24,45,46)]. With
regard to genomic rearrangements, there is evidence
from cell lines derived from breast cancers, that genomic
stability appears to be partially restored during tumor
development (47), consistent with the proposed model.
The concept that genomic instability might be restored
by RAD51 overexpression during tumor progression, as
previously suggested by the Bishop laboratory (24,48), has
been expanded here.
We also propose that cancers initiated by MMR defects
do not select for TP53 mutations. Such mutations might
up-regulate RAD51, which would be deleterious in
HRR-proﬁcient cells. Besides, in such cancers there is no
need to up-regulate RAD51 for suppression purposes, and
the precancerous cells achieve the additional beneﬁts of
TP53 inactivation, such as down-regulation of both
apoptosis and checkpoint functions, by selecting for
mutations in other genes that do not aﬀect RAD51
expression.
The model presented here, if correct, has profound
implications for how cancers might be treated more eﬀec-
tively in the future. Our proposed hypothesis argues that
many more cancers may arise from HRR defects than has
previously been suggested. If so, restoration of RAD51 to
normal levels (i.e. no longer suppressing the original HRR
defect) may sensitize these tumor cells to genotoxic agents
that kill HRR defective cells. Imatinib has been reported
to suppress the overexpression of RAD51, while not
strongly aﬀecting the levels of RAD51 in non-cancerous
cells (35). Imatinib sensitizes tumors to radiation and to
chemotherapy (34,35), and the model presented here
provides a new perspective on such cancer treatment,
that is based on the pro-oncogenic activity of RAD51
overexpression. Recently, PARP inhibitors have been
used to target tumors with HRR defects such as BRCA1
and BRCA2 (49). Since PARP inhibitors preferentially
target HRR-defective tumor cells, we propose that a com-
bination therapy using both imatinib-type compounds and
Figure 3. Schemes to explain the order of events in the two proposed models. (A) Model I: normal cells that develop an HRR defect
(e.g. BRCA1
 / ) select for loss of TP53, which then acts to up-regulate RAD51 expression (darker nuclei represent higher levels of RAD51).
Overexpression of RAD51 can in some cases lead to partial suppression of the original HRR defect, helping to stabilize the genome. (B) Model II: in
some cancers, TP53 mutations are early events and these mutations may up-regulate RAD51 expression, resulting in increased genomic instability.
Subsequent mutations/silencing in an HRR function partially suppresses the phenotype of RAD51 overexpression, reducing genomic instability. The
asterisk indicates that for sporadic cancers many of these HRR mutations are likely to be in genes that exhibit haploinsuﬃciency, or the mutations
themselves may be dominant-negative alleles.
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RAD51 overexpressing cancers.
MODEL II: RAD51 UP-REGULATION LEADS TO
GENOMIC INSTABILITY FIRST, FOLLOWED BY
SELECTION FOR INACTIVATION OF AN HRR
GENE TO RESTABILIZE THE GENOME
Overexpression of RAD51, like mutations in HRR, can
destabilize the genome (9), as previously discussed. An
alternative to Model I is that in some cancers the
up-regulation of RAD51 is an early event (Figures 3B
and 4B). Subsequently, as carcinogenesis proceeds, there
is selection for an HRR defect to speciﬁcally counteract
the eﬀects of RAD51 overexpression. The consequence of
each of these two proposed cancer developmental pro-
cesses (i.e. Models I and II) is the same (i.e. cells with
both an HRR defect and higher than normal levels
of RAD51 protein), but the order of events is reversed.
The alternative Model II helps to explain why in some
BRCA
+/  carriers, inactivation of the second BRCA
allele is a late event (50). This model suggests that in
cancers arising by this order of events, the BRCA
heterozygosity has little to do with the early events of
carcinogenesis, but is required to rescue highly unstable
cancer cells from the RAD51 up-regulation. It is impor-
tant to note that, although both models are mutually
exclusive to explain the origin of a single tumor, each
hypothesis may correctly explain the origin of some
cancers. For both sporadic and inherited
predisposition-related cancers, some may have evolved
with an HRR defect ﬁrst, while others may have evolved
ﬁrst with a TP53 mutation and/or other mutation that
up-regulates RAD51.
Although there appears to be no cancer-related
mutations in the RAD51 coding region, there is a single-
nucleotide polymorphism (SNP) in the 50-untranslated
region of RAD51 that increases the likelihood of breast
cancer in BRCA2
+/  carriers (51). This SNP has been
Figure 4. (A) Summary of Model I explaining cancer development initiated by HRR defects. The model suggests that many cancers with genomic
instability are initiated by HRR defects, just as cancers with MSI are initiated by MMR defects. In cancers with HRR defects, selection for
up-regulation of RAD51 acts to suppress the original HRR defect, partially restoring genomic stability and enhancing cell proliferation. TP53
mutations frequently result in the up-regulation of RAD51, and are selected for in cancers with a pre-existing HRR defect. HNPCC, hereditary
non-polyposis colorectal cancer. (B) Summary of Model II explaining cancer development initiated by RAD51 up-regulation. In this model, inac-
tivation of TP53 and up-regulation of RAD51 occur early in sporadic oncogenesis (i.e. cancers initiated by spontaneous non-inherited mutations)
(left side). In some BRCA heterozygous cells (BRCA1
+/  or BRCA2
+/ ), these events occur prior to functional loss of HRR resulting from a
mutation or silencing of the second BRCA allele (right side). These are identical models, with the exception of the underlined phrases.
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SNP-containing RAD51 transcripts ( 2–3-fold) for a
reporter construct expressed in the U2-OS osteosarcoma
cell line (52). The increased cancer predisposition of
BRCA2 carriers with this RAD51 SNP can be explained
by either of the two diﬀerent models presented. For each
model, the up-regulation of RAD51 is a necessary event
for carcinogenesis, and the reported RAD51 SNP may
help to facilitate this up-regulation.
FUTURE RESEARCH FOR EXAMINING RAD51
OVEREXPRESSION AND SUPPRESSION
There are a number of questions that should be experi-
mentally addressed to further examine RAD51
overexpression and complementation. (i) Which HRR
genes/defects are suppressed by RAD51 overexpression,
are all of these suppressible HRR defects in either recom-
bination mediator or co-mediator genes, and is there sup-
pression of mediators that also function at an additional
stage of HRR? (ii) Are elevated levels of RAD51AP1 and/
or RAD54 synergistic to RAD51 overexpression in this
suppression? (iii) In addition to TP53, TP63, TP73,
c-Abl and AP2, what other genes are involved in
regulating the expression of RAD51? (iv) Is RAD51
expression and/or activity regulated by translational
and/or post-translational mechanisms (presumably
fruitful areas for further study)? (v) Do most tumors
that overexpress RAD51 have suppressed HRR defects
and also TP53 mutations? (vi) If epigenetic silencing is
involved in inactivating HRR functions, can these
silencing events be reversed by drugs, and if so, is this
reversal lethal or semi-lethal to cancer cells with high
levels of RAD51 protein, even in the absence of genotoxic
agents?
There is also a great need for additional mechanisms to
assay for the levels of RAD51 transcript, protein and foci
in primary tumors. A recent study successfully analyzed
RAD51 foci, as well as BRCA1 and FANCD2 foci, in
sporadic breast cancer biopsies (treated with X-rays
ex vivo), and the absence of such foci was closely
correlated with likely defects in the BRCA1 pathway
(53). Improved mechanisms for analyzing RAD51 levels
and re-localization/DNA-damage foci should be useful in
the analyses of primary tumors and help to determine
potential treatment modalities.
CONCLUDING REMARKS
In summary, overexpression of RAD51 in a number of
diﬀerent organisms has been shown to partially suppress
defects in recombination mediator and co-mediator func-
tions. In addition, RAD51 is frequently up-regulated in
cancer cell lines and in primary tumors, although
RAD51 overexpression in the absence of any underlying
HRR defect is frequently detrimental to growth of cells, at
least in tissue culture.
Largely based on the published ﬁndings reviewed here,
two closely related models are proposed that may help
to explain the role of RAD51 up-regulation in cancers.
It is worth remembering that cancer is an extremely
complex set of diseases, and that cancer cells develop
many diﬀerent mechanisms to achieve the same phenotype
of independent and uncontrolled growth (54,55). The
models presented here strive to explain certain aspects of
oncogenic progression, and if these models prove correct,
they will point the way to how some cancers arise and to
novel roles for HRR functions during oncogenesis.
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